Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


J&J drug offers hope in advanced prostate cancer

Men with advanced prostate cancer lived nearly four months longer on a new pill from Johnson & Johnson, according to keenly awaited study data that researchers said would change clinical practice.

Abiraterone, which could reach the market next year, provides a new option for men with an aggressive type of prostate cancer.

Its… J&J drug offers hope in advanced prostate cancer   

J&J’s prostate cancer drug approved in EU

Johnson & Johnson’s prostate cancer drug Zytiga has been approved in the European Union, paving the way for the launch of a new treatment for men whose disease has progressed after chemotherapy, the company said on Wednesday.

The decision was expected after European regulators endorsed the treatment in July. J&J’s Janssen unit has European… J&J’s prostate cancer drug approved in EU   

prostate cancers1 - cryptorchidism1 - circumcised men1 - adrenocortical carcinoma1 - sexually transmitted infections1 - nephrolithotomy1 - adequate erection1 - risk of cancer1 - invasive treatment1 - avandia1 - fsgs2 - smoking1 - severe hypocitraturia1 - ontario health insurance plan1 - urinary calculi3 - sexually transmitted disease1 - journal pediatric nephrology1 - autism spectrum disorder1 - artificial urinary sphincter1 - hormone erythropoietin1 - urgency7 - cause of incontinence6 - renal calyx1 - immunosuppressive therapy1 - prolapse symptoms3 - citric acid1 - human vaccine1 - urethrotomy1 - extracorporeal shockwave lithotripsy1 - bladder control4 -